A Case of Interstitial Pneumonitis and Pancytopenia Following the Combination Therapy of Pegylated Interferon and Ribavirin.
- Author:
Ji Hyun SUH
1
;
Sung Hwahn HAHN
;
Ji Eun LEE
;
Jin Hyung HAN
;
Kyung Mook KIM
;
Doh Hyung KIM
;
Yon Seop KIM
;
Jae Suk PARK
;
Young Koo JEE
Author Information
- Publication Type:Case Report
- Keywords: Hepatitis C, Chronic; peginterferon alfa-2a; Ribavirin; Pancytopenia; Interstitial Lung Diseases
- MeSH: Anemia, Hemolytic; Arthralgia; Fever; Headache; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Korea; Lung Diseases, Interstitial; Pancytopenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin
- From:Tuberculosis and Respiratory Diseases 2011;70(1):69-73
- CountryRepublic of Korea
- Language:Korean
- Abstract: The combination therapy of pegylated interferon and ribavirin is the mainstay of treatment for chronic hepatitis C patients. Anti-viral therapy is commonly associated with side effects such as headache, fever, myalgia, and arthralgia. However, anti-viral therapy can continue because these side effects are mostly mild and can be improved with supportive management. Anti-viral therapy should be stopped promptly if serious side effects, such as interstitial pneumonitis or hemolytic anemia occur, although those serious side effects are rare. There were a few case reports of interferon-related interstitial pneumonitis worldwide. In Korea, one atypical case report of interstitial pneumonitis has been reported, which followed the combination therapy of interferon-alpha and ribavirin in a patient with chronic hepatitis C. We present a case of interstitial pneumonitis and pancytopenia following the combination therapy of pegylated interferon and ribavirin in a patient with chronic hepatitis C.
